​

Bio-Rad Laboratories (BIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIO Stock Forecast

Bio-Rad Laboratories (BIO) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $340.00, with a high of $340.00 and a low of $340.00. This represents a 8.29% increase from the last price of $313.97.

$265 $284 $303 $322 $341 $360 High: $340 Avg: $340 Low: $340 Last Closed Price: $313.97

BIO Stock Rating

Bio-Rad Laboratories stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 1 Strong Buy (7.14%), 8 Buy (57.14%), 5 Hold (35.71%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 5 8 1 Strong Sell Sell Hold Buy Strong Buy

BIO Price Target Upside V Benchmarks

TypeNameUpside
StockBio-Rad Laboratories8.29%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks19.58%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$340.00$340.00
Last Closing Price$313.97$313.97$313.97
Upside/Downside-8.29%8.29%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-23--5
Nov, 25-23--5
Oct, 25-23--5
Sep, 25123--6
Aug, 25222--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2025Wells Fargo$340.00$319.476.43%8.29%
Oct 01, 2024Patrick DonnellyCitigroup$400.00$338.5818.14%27.40%
Dec 07, 2022RBC Capital$565.00$399.5941.39%79.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2025CitigroupBuyBuyhold
Oct 30, 2025Wells FargoCautiousCautioushold
May 02, 2025CitigroupBuyBuyhold
Oct 31, 2024RBC CapitalOutperformOutperformhold
Oct 31, 2024CitigroupBuyBuyhold
Oct 01, 2024Wells FargoBuyBuyhold
Oct 01, 2024CitigroupNeutralBuyupgrade
Aug 27, 2024Wells FargoEqual-Weightinitialise
Jun 03, 2024JefferiesHolddowngrade
Apr 03, 2024CitigroupNeutraldowngrade

Financial Forecast

EPS Forecast

$-150 $-90 $-30 $30 $90 $150 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$127.86$142.61$-121.79$-21.82$-65.36----
Avg Forecast$9.81$15.31$14.39$11.48$10.29$11.51$13.08$15.10$17.35
High Forecast$9.86$15.39$14.50$11.58$10.34$11.54$13.19$15.22$17.49
Low Forecast$9.74$15.20$14.28$11.40$10.23$11.47$12.99$14.99$17.22
Surprise %1203.36%831.48%-946.35%-290.07%-735.18%----

Revenue Forecast

$2B $3B $3B $3B $3B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.55B$2.92B$2.80B$2.67B$2.57B----
Avg Forecast$2.44B$2.89B$2.82B$2.68B$2.58B$2.65B$2.78B$2.92B$3.07B
High Forecast$2.45B$2.90B$2.83B$2.69B$2.59B$2.67B$2.78B$2.93B$3.09B
Low Forecast$2.43B$2.87B$2.80B$2.66B$2.56B$2.64B$2.78B$2.91B$3.05B
Surprise %4.22%1.27%-0.51%-0.16%-0.48%----

Net Income Forecast

$-4B $-2B $-600M $1B $3B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.81B$4.25B$-3.63B$-637.32M$-1.84B----
Avg Forecast$2.89B$2.27B$-2.01B$-637.32M$300.42M$336.13M$382.24M$441.19M$506.78M
High Forecast$3.47B$3.28B$-696.16M$-220.77M$302.16M$337.14M$385.18M$444.58M$510.83M
Low Forecast$2.31B$1.26B$-3.32B$-1.05B$298.67M$335.11M$379.29M$437.79M$503.03M
Surprise %32.01%87.55%80.50%--713.88%----

BIO Forecast FAQ

Is Bio-Rad Laboratories stock a buy?

Bio-Rad Laboratories stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 8 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bio-Rad Laboratories is a favorable investment for most analysts.

What is Bio-Rad Laboratories's price target?

Bio-Rad Laboratories's price target, set by 14 Wall Street analysts, averages $340 over the next 12 months. The price target range spans from $340 at the low end to $340 at the high end, suggesting a potential 8.29% change from the previous closing price of $313.97.

How does Bio-Rad Laboratories stock forecast compare to its benchmarks?

Bio-Rad Laboratories's stock forecast shows a 8.29% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (19.58%).

What is the breakdown of analyst ratings for Bio-Rad Laboratories over the past three months?

  • December 2025: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.

What is Bio-Rad Laboratories’s EPS forecast?

Bio-Rad Laboratories's average annual EPS forecast for its fiscal year ending in December 2025 is $11.51, marking a -117.61% decrease from the reported $-65.36 in 2024. Estimates for the following years are $13.08 in 2026, $15.1 in 2027, and $17.35 in 2028.

What is Bio-Rad Laboratories’s revenue forecast?

Bio-Rad Laboratories's average annual revenue forecast for its fiscal year ending in December 2025 is $2.65B, reflecting a 3.45% increase from the reported $2.57B in 2024. The forecast for 2026 is $2.78B, followed by $2.92B for 2027, and $3.07B for 2028.

What is Bio-Rad Laboratories’s net income forecast?

Bio-Rad Laboratories's net income forecast for the fiscal year ending in December 2025 stands at $336.13M, representing a -118.23% decrease from the reported $-1.844B in 2024. Projections indicate $382.24M in 2026, $441.19M in 2027, and $506.78M in 2028.